Stevanato Group S.p.A. (STVN)
USD 21.38
(3.09%)
USD 21.38
(3.09%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 139.17 Million EUR | 4.42% |
| 2022 | 127.4 Million EUR | 23.57% |
| 2021 | 103.1 Million EUR | 13.21% |
| 2020 | 91.06 Million EUR | 20.14% |
| 2019 | 75.8 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 35.26 Million EUR | -1.15% |
| 2024 Q2 | 37.52 Million EUR | 19.82% |
| 2023 Q1 | 35.61 Million EUR | -4.02% |
| 2023 FY | 133.03 Million EUR | 4.42% |
| 2023 Q4 | 35.67 Million EUR | 12.53% |
| 2023 Q3 | 31.7 Million EUR | -7.04% |
| 2023 Q2 | 34.1 Million EUR | -4.24% |
| 2022 Q2 | 30.73 Million EUR | 4.07% |
| 2022 Q1 | 29.53 Million EUR | 0.11% |
| 2022 FY | 127.4 Million EUR | 23.57% |
| 2022 Q4 | 37.1 Million EUR | 23.73% |
| 2022 Q3 | 29.98 Million EUR | -2.44% |
| 2021 Q1 | 22.47 Million EUR | 8.55% |
| 2021 FY | 103.1 Million EUR | 13.21% |
| 2021 Q4 | 29.5 Million EUR | -15.81% |
| 2021 Q3 | 35.04 Million EUR | 117.71% |
| 2021 Q2 | 16.09 Million EUR | -28.37% |
| 2020 Q4 | 20.7 Million EUR | -15.62% |
| 2020 FY | 91.06 Million EUR | 20.14% |
| 2020 Q3 | 24.53 Million EUR | 12.98% |
| 2020 Q2 | 21.71 Million EUR | -9.98% |
| 2020 Q1 | 24.12 Million EUR | 0.0% |
| 2019 FY | 75.8 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alcon Inc. | 4.2 Billion USD | 96.693% |
| AptarGroup, Inc. | 814.37 Million USD | 82.91% |
| Baxter International Inc. | 5.27 Billion USD | 97.36% |
| Becton, Dickinson and Company | 6.04 Billion USD | 97.698% |
| Bausch + Lomb Corporation | 2.37 Billion USD | 94.138% |
| Haemonetics Corporation | 526.66 Million USD | 73.575% |
| Envista Holdings Corp | 1.15 Billion USD | 87.905% |
| ResMed Inc. | 1.36 Billion USD | 89.829% |
| Teleflex Incorporated | 1.08 Billion USD | 87.164% |
| Warby Parker Inc. | 437.22 Million USD | 68.169% |
| West Pharmaceutical Services, Inc. | 454 Million USD | 69.345% |